Summary In photodynamic therapy (PDT), photosensitisers accumulate somewhat preferentially in malignant tissues; photoactivation with appropriate wavelength of light releases toxic molecular species which lead to tumour tissue death. In order to target ovarian cancer with increased specificity, a chlorin-based photosensitiser (chlorin e6 monoethylendiamine monoamide) was conjugated to OC125, a monoclonal antibody recognising an antigen expressed in 80% of non-mucinous ovarian cancers. In previous work, this immunoconjugate (IC) was shown to be selectively phototoxic to cancer cells from ovarian cancer patients ex vivo and to localise preferentially in ovarian cancer tissue in vivo. In this study we report results from in vivo phototoxicology and photodynamic treatment studies using this IC in a murine model for ovarian cancer. A comparison of single vs multiple treatments was also made. For in vivo experimentation, Balb C nude mice were injected with 30 x 106 NIH:OVCAR 3 cancer cells to create an ascitic tumour model. Animals were then given intraperitoneal injections of the immunoconjugate (0.5 mg kg-'). Twenty-four hours later the intraperitoneal surfaces were exposed to 656 nm light from an argon-ion pumped-dye laser (50 mW, 656 nm), using a cylindrical diffusing tip fibre. The overall treatment was given either once or multiply. No animals died from treatment complications. Twenty-four hours following one and three PDT treatments, the percentage of viable tumour cells in the ascites of the treated animals analysed ex vivo was 34% and 5% of control for one and three treatments respectively. With respect to survival, all control mice (n = 18) died between 30 and 50 days. However, for those treated three times (n = 10), 40% were still alive after 50 days, and for those treated four times (n= 12) 58% were alive after 50 days. Evaluation with log-rank test revealed a significant survival with intraperitoneal PDT compared with controls (P= 0.0006). These preliminary results suggest that PDT with an OC125 immunoconjugate may be an effective therapy for the management of advanced ovarian cancer. Clinical application of this therapy needs to be further optimised and may require multiple treatments, similar to fractionated radiation therapy and cyclic chemotherapy, in order to control malignant disease with acceptable toxicity to normal tissue.
Summary In photodynamic therapy (PDT), photosensitisers accumulate somewhat preferentially in malignant tissues; photoactivation with appropriate wavelength of light releases toxic molecular species which lead to tumour tissue death. In order to target ovarian cancer with increased specificity, a chlorin-based photosensitiser (chlorin e6 monoethylendiamine monoamide) was conjugated to OC125, a monoclonal antibody recognising an antigen expressed in 80% of non-mucinous ovarian cancers. In previous work, this immunoconjugate (IC) was shown to be selectively phototoxic to cancer cells from ovarian cancer patients ex vivo and to localise preferentially in ovarian cancer tissue in vivo. In this study we report results from in vivo phototoxicology and photodynamic treatment studies using this IC in a murine model for ovarian cancer. A comparison of single vs multiple treatments was also made. For in vivo experimentation, Balb C nude mice were injected with 30 x 106 NIH:OVCAR 3 cancer cells to create an ascitic tumour model. Animals were then given intraperitoneal injections of the immunoconjugate (0.5 mg kg-'). Twenty-four hours later the intraperitoneal surfaces were exposed to 656 nm light from an argon-ion pumped-dye laser (50 mW, 656 nm), using a cylindrical diffusing tip fibre. The overall treatment was given either once or multiply. No animals died from treatment complications. Twenty-four hours following one and three PDT treatments, the percentage of viable tumour cells in the ascites of the treated animals analysed ex vivo was 34% and 5% of control for one and three treatments respectively. With respect to survival, all control mice (n = 18) died between 30 and 50 days. However, for those treated three times (n = 10), 40% were still alive after 50 days, and for those treated four times (n= 12) 58% were alive after 50 days. Evaluation with log-rank test revealed a significant survival with intraperitoneal PDT compared with controls (P= 0.0006). These Ovarian cancer is a disease which is largely confined to the peritoneal cavity and, therefore, may be amenable to localised therapies which have tumour cell selectivity. Photodynamic therapy (PDT) is an experimental approach to the treatment of neoplasms which may alleviate some of the problems associated with the lack of specificity of conventional therapies. PDT involves the use of non-toxic compounds, photosensitisers, which are preferentially retained in malignant tissues by a variety of mechanisms (Dougherty, 1987; Hasan and Parrish, 1996) . Exposure to the appropriate wavelength of light activates the photosensitiser to release toxic substances such as singlet oxygen, which result in phototoxicity and tumour cell death (Henderson and Dougherty, 1992; Pass, 1993) . PDT provides increased selectivity by combining photosensitiser localisation to the tumour with spatial control of illuminated areas. In theory, this should minimise damage to normal tissue.
Photodynamic treatment of ovarian cancer in experimental animals was initially described by Tochner et al. (1985, 1986) . Using the photosensitiser, haematoporphyrin derivative (HPD) and intraperitoneal light, these investigators showed effective eradication of a syngeneic murine ascites tumour (embryonal ovarian carcinoma) in 17 of 20 animals with four treatments of HPD and intraperitoneal exposure to light. These results prompted phase I trials of PDT using a Correspondence: T Hasan, Massachusetts General Hospital, relatively purified form of HPD, Photofrin (PF), for the treatment of disseminated intraperitoneal malignancies (Sindelar et al., 1991; Delaney et al., 1993) . In this study 18 women with ovarian cancer were treated with PF and PDT; four of the 18 achieved a complete response. Toxicity in this trial was primarily related to the non-specific uptake of the photosensitiser. In addition to prolonged skin phototoxicity which persists for 30-60 days, small bowel perforations developed at anastomotic sites. Other investigators have shown that HPD is not selectively retained in human ovarian cancers implanted subcutaneously (Peterson et al., 1992) . These problems of non-specific localisation have prompted the search for new photosensitisers with improved specificity (Gomer, 1991) .
One way to improve target specificity of phototoxic compounds is to link them with tumour-specific monoclonal antibodies (Mew et al., 1983; Hasan, 1992) . In previous studies we have reported the conjugation of a chlorin photosensitiser site specifically to the monoclonal antibody OC125 (Hasan et al., 1989; Goff et al., 1991) . Chlorin derivatives are efficient photosensitisers with a high yield of singlet oxygen. OC125 recognises the antigen CA125, which is expressed by 80% of non-mucinous ovarian cancers (Bast et al., 1981) . The conjugate was significantly more phototoxic to ovarian cancer cells both in vitro (cell lines) and ex vivo (from cancer patients), while exhibiting very little phototoxicity to CA125-negative cells (Goff et al., 1991 (Goff et al., , 1992 . Biodistribution assays of the immunoconjugate in an ascitic Balb/C nude mouse model injected with human ovarian cancer were reported previously (Goff et al., 1994) . In this present study we report our experience with photoimmunotherapy using an OC 125 immunoconjugate and intraperitoneal light in the nude mouse ascitic ovarian cancer model. (Hamilton et al., 1983) . The monoclonal antibody OC125 was a generous gift of Centocor (Malvern, PA, USA). Cells were grown in RPMI-1640 medium (Gibco, Grand Island, NY, USA) supplemented with heat-inactivated fetal bovine serum and kept in an incubator at 37°C in an atmosphere of 5% carbon dioxide. For tumour transplantation, cells were trypsinised (Trypsin-EDTA, Gibco), centrifuged at 1000 r.p.m. for 10 min (Model 6000B, Sorval Centrifuges, Dupont, Wilmington, DE, USA), and resuspended in 1 ml of phosphatebuffered saline (PBS, Gibco) for intraperitoneal injection.
Tumour model Experiments were carried out in a murine model for ovarian cancer developed by Hamilton et al. (1984) . Balb/C athymic nude mice (Charles River Breeding Laboratories) were given intraperitoneal injections of 30 x 106 NIH:OVCAR 3 cells. This results in the development of serosal metastases similar to that of ovarian cancer in humans. Disease progression is characterised by the development of massive ascites and extensive intraperitoneal tumours. Within several weeks, animals develop clinical evidence of ascites. Animals which became moribund were terminated. All animal experiments were approved by the Massachusetts General Hospital Animal Care Committee and guidelines for the care and use of animals approved by the Institution were followed.
Photosensitiser
The photosensitiser used was a chlorin derivative, chlorin e6 monoethylendiamine monamide (CMA). CMA was obtained from Porphyrin Products (Logan, UT, USA). The monoclonal antibody OC125 was a gift from Centocor (Malvern, PA, USA). The immunoconjugate was synthesised by a reaction at the carbohydrate moiety as previously described (Goff et al., 1991) . Briefly, polyglutamic acid (PGA) (Sigma, St Louis, MO, USA) is bound to the CMA. The PGA-CMA is then covalently linked to the carbohydrate moiety at the hinge region of the monoclonal antibody away from the antigen-binding sites.
Photoxicology studies Mice were injected with 30 million NIH:OVCAR 3 cells. Seven days after injection, animals were given an intraperitoneal injection of the immunoconjugate (0.5-4.0 mg kg-1). Animals were immobilised and externally irradiated with an argon-ion pumped-dye laser (Coherent Inc., Palo Alto, CA, USA) at a wavelength of 656 nm (Lmax CMA). Exposure to light was performed at 24 h based upon optimal tumour to non-tumour ratios from biodistribution studies (Goff et al., 1994) . The power density was 40 -70 mW cm-2 and the fluence administered was 10-75 J cm-2. External irradiation was easily employed for these initial studies because there was no violation of the peritoneal cavity. Also in nude mice, the abdominal wall is thin (< 2 mm) so that it presents a minimal barrier to 656 nm irradiation.
Photodynamic treatment in vivo Mice were injected with 30 million NIH:OVCAR 3 cells. Seven days after injection, animals were given an intraperitoneal injection of immunoconjugate (0.5-2.0 mg kg-'); controls were injected with sterile PBS. Twenty-four h later animals were sedated with sodium pentobarbital and intraperitoneal irradiation with an argon-ion pumped-dye laser (Coherent Inc., Palo Alto, CA, USA) was carried out using a cylindrically diffusing tip fibre as described by Tochner et al. (1985, 1986 Iodine-131-labelled OC125 has been studied in phase I trials The median survival for the control animals (n = 18) to treat recurrent ovarian cancer (Muto et al., 1992) . days, and all controls died between 30 and 50 days.
However, the efficacy of these immunoconjugates remains nice treated with three treatments, 40% were alive to be established. In experimental models, for doses that are lays and the median survival was 47.5 days. For curative or inhibit tumour progression, systemic toxicity from ted with four treatments, 58% were alive after 50 bound toxins and radioisotopes remains a significant problem median survival was 58.0 days. Evaluation with logbecause most monoclonal antibodies lack sufficient specificity t revealed significant survival advantage with to preclude damage to normal organs.
)neal PDT compared with controls (P = 0.0006).
Although PDT can, in principle, be more selective than Dn, there was a trend towards improved survival some other modalities for cancer treatment, sites such as the vs three treatments (P = 0.1).
peritoneal cavity are complex physically and optically. It is Isies of the animals from survival studies show that this complexity that may be responsible for toxicity problems ontrol animals die with massive ascites and a large noted clinically (Sindelar et al., 1991; Delaney et al., 1993) in lurden compared with 27% of the treated animals.
the intraperitoneal PDT with PF. Selective destruction of maining 73% of the treated animals, the cause of target tissue in such situations requires a higher preferential )eared secondary to the tumour. However, ascites tumour localisation by the photosensitiser than afforded by abdominal tumours were much less extensive. The PF. Even second generation photosensitisers, such as mour persistence in the treated group was in the benzoporphyrin derivative monoacid, do not offer much domen around the liver and stomach, probably improved selectivity for this disease (Molpus et al., 1996) . In diminished light delivery and penetration.
the early clinical trials using intraperitoneal PDT with PF, there was substantial third spacing of fluids (Delaney et al., 1993) . Most patients exhibited fluid sequestration greater than would be expected in a normal post-operative course, and all developed significant hypoalbuminaemia (Sindelar et cancer is the fifth most frequently occurring fatal al., 1991). In addition, 59% of the patients treated with the United States. The majority of patients present intraperitoneal PDT developed pleural effusions post-opera-III disease, and even with aggressive cytoreductive tively, and 15% required thoracentesis or prolonged ad chemotherapy, 5 year survival rates are only 15-intubation. In a recent study by Takita et al. (1994) ,ently, monoclonal antibody conjugates have been evaluating PDT with PF for malignant pleural mesothelioor both tumour localisation and treatment in ovarian mas, the authors noted that there were excessive fluid dium-l 11-labelled OC125 has been used for tumour requirements for the first 24 h following PDT, which also suggests that substantial third spacing (capillary leaking) occurs following PDT. These earlier studies may provide an explanation as to why the mice in our study appeared to suffer acute circulatory collapse following high doses of PDT. al., 1992) . The murine malignant ascites model used for our experiments is far more complex, but it also more closely resembles advanced ovarian cancer in women. Not surprisingly, we were not able to eradicate intraperitoneal tumour deposit completely in this initial study. Undoubtedly, the practical challenges posed by the intraperitoneal murine experiments, such as delivery of light, interactions with viscera and fluid third-spacing, will require refinements in technique.
In summary, our initial in vivo results using this murine model, particularly the selective phototoxicity to human ovarian cancer cells and improved survival after fractionated PDT treatments are encouraging and warrant further studies. However, the fact that even after four treatments, 5% of the cancer cells appeared to be viable, at least in the acute toxicity testing, suggests that significant optimisation of the treatment is still necessary. The observation that, in treated animals, the site of tumour persistence was predominantly in the upper abdomen around the liver and stomach suggests that adequate delivery of light was a problem. Clearly, more quantitative light delivery and dosimetry are necessary to reduce phototoxic death from generalised irradiation of the peritoneal cavity. These issues are currently being addressed (Lilge et al., 1994) using multiple fibres for delivery and dosimetry. There is also ample room for the improvement of tumour uptake of the OC125 immunoconjugate. CA125 is expressed by many normal tissues and this antigen is shed efficiently (Bast et al., 1981 (Bast et al., , 1983 . The use of more specific antibodies, such as to products of oncogenes, or antibody cocktails should improve the efficacy of PDT. The multiple application of murine antibodies would pose another potential problem. However, chimeric antibodies may further enhance uptake and reduce the formation of human anti-murine antibodies, which can interfere with therapies that would require multiple treatments (Muto et al., 1990) . Because of the limited tissue penetration (-5 mm) of 656 nm light (Star et al., 1992) , the most useful application of photoimmunotherapy clinically will be for the eradication of small residual disease following cytoreductive surgery, microscopic disease or diaphragmatic studding. This treatment option may be especially promising in patients with minimal disease at the time of second-look laparotomy, since PDT has been shown to be phototoxic to human ovarian cancer cells that are platinum resistant (Pass, 1993; Goff et al., 1991) .
